Anti-programmed death receptor-1 (PD-1), anti-programmed death ligand-1 (PD-L1) and anti-cytotoxic T-lymphocyte protein 4 (CTLA4) have been developed to inhibit immune checkpoint pathways in order to prime anti-tumor activity of cytotoxic T-cells. The gene discussed is CTLA4; the disease is neoplasm.